Novopulmon Novolizer (Budesonide)

Budesonide binds to glucocorticoid receptors inside airway cells, altering gene expression to suppress the production of inflammatory mediators. This reduces the recruitment of immune cells, decreases mucus production, and stabilises the airway lining, resulting in less swelling and improved airflow.

The dose of Novopulmon Novolizer is individualized by the prescribing healthcare professional based on the severity of the patient’s condition, age, and response to therapy. Patients should follow the specific instructions provided by their doctor or respiratory therapist.

Safety in pregnancy and lactation has not been fully established. The prescribing clinician will weigh the potential benefits against any possible risks to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Novopulmon Novolizer delivers budesonide, a potent inhaled corticosteroid with a favorable safety profile and high lung deposition. Compared with some alternatives, budesonide has a relatively low systemic bioavailability, which may reduce the risk of systemic side effects while providing effective anti‑inflammatory control.

Store the device at temperatures below 30 °C, in its original packaging, and protect it from moisture and direct sunlight. Do not expose the inhaler to extreme heat or humidity, as this could affect the powder’s integrity and dosing accuracy.

Novopulmon Novolizer is a dry‑powder inhaler. The patient exhales fully, places the mouthpiece in the mouth, seals lips around it, and inhales sharply and deeply to draw the powder into the lungs. After each dose, it is recommended to rinse the mouth with water and spit to reduce oral irritation.

Serious risks include adrenal suppression, especially with high‑dose or prolonged use, and an increased susceptibility to infections such as pneumonia or oral candidiasis. Rarely, paradoxical bronchospasm or severe allergic reactions may occur. Patients should be monitored for signs of these events and report them promptly.

Novopulmon Novolizer is contraindicated in individuals with a known hypersensitivity to budesonide or any component of the inhaler device. It should also be avoided in patients with active, untreated infections of the respiratory tract, including tuberculosis, unless the benefits outweigh the risks as determined by a physician.